Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul 12;5(1):e2013051.
doi: 10.4084/MJHID.2013.051. Print 2013.

The Role of Bleeding History and Clinical Markers for the Correct Diagnosis of VWD

Affiliations

The Role of Bleeding History and Clinical Markers for the Correct Diagnosis of VWD

Alberto Tosetto. Mediterr J Hematol Infect Dis. .

Abstract

Quantification of the bleeding severity by use of bleeding assessment tools (BAT) and bleeding score (BS) has been consistently shown to improve the clinical diagnosis of von Willebrand disease (VWD) while helping researchers establish phenotype/genotype correlations. Subjects with a BS equal or higher than 3 may be consider having a bleeding tendency, and should be referred for a laboratory investigation, particularly for VWD. In the diagnosis of type 1 VWD, the use of the BS has been shown to be highly specific (>95%) with reported sensitivities ranging from 40 to 100%. The BS is related to all available measurements of von Willebrand factor activity, including the PFA-100 closure time. Therefore, in clinical practice the use of BAT should always be the first step to standardize the assessment of patients with suspected VWD. The use of the recent ISTH consensus BAT is suggested to harmonize the collection of bleeding symptoms in patients with a suspected or confirmed hemostatic disorder, particularly VWD. The ISTH BAT is also coupled with a Web-based repository of bleeding symptoms, therefore providing an integrated framework for collaboration in the field of clinical evaluation of VWD and mild bleeding disorders.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Castaman G, Rodeghiero F. Advances in the diagnosis and management of type 1 von Willebrand disease. Expert Rev Hematol. 2011;4:95–106. doi: 10.1586/ehm.11.1. - DOI - PubMed
    1. Sadler JE, Rodeghiero F. Provisional criteria for the diagnosis of VWD type 1: on behalf of the ISTH SSC Subcommittee on von Willebrand Factor. J Thromb Haemost. 2005;3:775–777. doi: 10.1111/j.1538-7836.2005.01245.x. - DOI - PubMed
    1. Mauser Bunschoten EP, van Houwelingen JC, Sjamsoedin Visser EJ, van Dijken PJ, Kok AJ, Sixma JJ. Bleeding symptoms in carriers of hemophilia A and B. Thromb Haemost. 1988;59:349–352. - PubMed
    1. Quiroga T, Goycoolea M, Panes O, Aranda E, Martinez C, Belmont S, Munoz B, Zuniga P, Pereira J, Mezzano D. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica. 2007;92:357–365. doi: 10.3324/haematol.10816. - DOI - PubMed
    1. Silwer J. von Willebrand’s disease in Sweden. Acta Paediatr Scand Suppl. 1973;238:1–159. - PubMed

LinkOut - more resources